Barclays plans 14-month Accelerated Return Notes tied to biotech stocks

By Susanna Moon

Chicago, Nov. 18 – Barclays Bank plc plans to price 0% Accelerated Return Notes due January 2016 linked to basket of three equally weighted biotechnology sector stocks, according to an FWP filing with the Securities and Exchange Commission.

The underlying companies are Biogen Idec Inc., Celgene Corp. and Gilead Sciences, Inc.

The payout at maturity will be par of $10 plus triple any basket gain, up to a maximum return of 18% to 22%. The exact cap will be set at pricing.

Investors will be exposed to any losses.

BofA Merrill Lynch is the agent.

The notes will price in November and settle in December.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.